Opportunistic Genetic Testing for Familial Hypercholesterolemia in Premature Acute Coronary Syndrome: Results of the ACCURATE Study
Authors' conclusion
Opportunistic genetic testing of young adults with ACS was associated with increased FH diagnosis, more intensive lipid-lowering treatment, and improved lipid target attainment. (Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia [ACCURATE]; NCT05218005).
Study context
- Population
- Patients <60 years old admitted with acute coronary syndrome (ACS) and low-density lipoprotein cholesterol (LDL-C) ≥4 mmol/L (≥155 mg/dL)completed the study · phase 1 40 · phase 2 100
- Participants
- 40 vs 100
- Exposure
- phase 1 vs phase 2
- phase 1n = 40
- phase 2n = 100
- Outcome
- New diagnosis of definite FH
- Follow-up
- 15 months post-ACS
Methodological details2 sequential cohorts
- 2 sequential cohorts
Main finding
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
LDL-C <1.8 mmol/L · 15 months · more likely with phase 2
P = 0.04
Receiving statin therapy · 15 months · more likely with phase 2
P = 0.04
Receiving statin-ezetimibe combination therapy · 15 months · more likely with phase 2
P = 0.02
Mean LDL-C · 15 months · lower with phase 2
P = 0.03
mg/dL phase 1 75 mg/dL · phase 2 64 mg/dL
Original publication
Summarised from the published abstract; every number is checked against it